Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 7/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494013 | 0.87 | NR3C1 (0.64) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5584588 | 0.86 | NR3C1 (0.43) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| Ammonia Solution, Strong SCHEMBL7288975 | 0.85 | NR3C1 (0.62) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5584959 | 0.85 | QDPR (0.43) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5584589 | 0.85 | NR3C1 (0.42) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9188312 | 0.83 | NR3C1 (0.60) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9325871 | 0.81 | PDE4A (0.59) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5584986 | 0.80 | PTAFR (0.53) | PTAFR | |
| SCHEMBL2473309 | 0.79 | PDE4B (0.64) | NR3C1PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL9772895 | 0.77 | PDE4B (0.62) | NR3C1PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1188747-B1 | PHENOXYPROPYLAMINE COMPOUNDS | MITSUBISHI PHARMA CORP (JP) | 2005-09-07 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | NR3C1 157/4885PDE4A 921/4885PDE4B 1179/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NR3C1 26/4885PDE4A 4145/4885PDE4B 3738/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | NR3C1 157/4885PDE4A 921/4885PDE4B 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.